Royalty Pharma (RPRX) Interest & Investment Income (2019 - 2026)

Royalty Pharma has disclosed Interest & Investment Income across 8 years of filings, most recently posting $6.2 million for Q1 2026.

• Interest & Investment Income for Q1 2026 came in at $6.2 million, down 44.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $28.5 million (down 44.29% YoY), and the FY2025 annual result was $33.6 million, down 29.05% from the prior year.
• Interest & Investment Income came in at $6.2 million for Q1 2026 at Royalty Pharma, down from $7.1 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $43.9 million in Q4 2022 to a low of $6.2 million in Q1 2026.
• The 5-year median for Interest & Investment Income is $10.9 million (2022), against an average of $14.0 million.
• Across the five-year window, Interest & Investment Income surged 312.19% in 2022 and tumbled 85.18% in 2023, its largest moves.
• Royalty Pharma's Interest & Investment Income stood at $43.9 million in 2022, then sank by 85.18% to $6.5 million in 2023, then surged by 39.03% to $9.0 million in 2024, then decreased by 21.76% to $7.1 million in 2025, then slipped by 11.91% to $6.2 million in 2026.
• The last three Interest & Investment Income figures came in at $6.2 million (Q1 2026), $7.1 million (Q4 2025), and $6.9 million (Q3 2025), per Business Quant data.